Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.00

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the five brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $20.00.

Several equities research analysts have issued reports on the stock. JMP Securities reiterated a "market outperform" rating and set a $22.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday. Evercore ISI raised shares of Enanta Pharmaceuticals to a "strong-buy" rating in a report on Tuesday, August 6th. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday. Finally, JPMorgan Chase & Co. dropped their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a research note on Tuesday, August 6th.

Enanta Pharmaceuticals Price Performance

ENTA stock traded up $0.41 during mid-day trading on Friday, reaching $11.04. 142,265 shares of the company traded hands, compared to its average volume of 207,562. The company has a fifty day moving average price of $11.92 and a 200-day moving average price of $13.22. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $17.80. The company has a market capitalization of $233.82 million, a P/E ratio of -1.77 and a beta of 0.58.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.36. The business had revenue of $17.97 million during the quarter, compared to analysts' expectations of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The firm's revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the business earned ($1.27) earnings per share. As a group, analysts forecast that Enanta Pharmaceuticals will post -5.3 EPS for the current year.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of the company's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the sale, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 13.64% of the stock is owned by corporate insiders.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ENTA. Vanguard Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock worth $33,664,000 after buying an additional 134,292 shares during the period. American Century Companies Inc. increased its position in shares of Enanta Pharmaceuticals by 35.4% in the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock valued at $362,000 after acquiring an additional 7,287 shares during the period. Rhumbline Advisers raised its stake in shares of Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock valued at $448,000 after acquiring an additional 1,548 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Enanta Pharmaceuticals by 13.3% during the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company's stock worth $958,000 after purchasing an additional 8,645 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Enanta Pharmaceuticals in the second quarter worth about $35,000. Institutional investors own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.